Skip to main content



) --




) hit a new 52-week high Wednesday as it traded at $25.50 compared with its previous 52-Week high of $25.49. Cepheid is changing hands at $25.49 with 518,099 shares traded as of 3:26 p.m. ET. Average volume has been 327,600 shares over the past 30 days.

Cepheid has a market cap of $1.5 billion and is part of the


sector and


TheStreet Recommends

industry. Shares are up 8.6% year to date as of the close of trading on Tuesday.

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets. The company has a P/E ratio of 127, above the S&P 500 P/E ratio of 23.2.

TheStreet Ratings rates Cepheid as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. You can view the full

Cepheid Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center